Skip to main content
Veterinary Medicines

EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live

Product identification

Medicine name:
EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
Eurican DAPPi Lyofilisaat en oplosmiddel voor suspensie voor injectie
Eurican DAPPi Lyophilisat et solvant pour suspension injectable
Eurican DAPPi Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
    4.70
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Plastic box of 10 vials of lyophilisate (1 dose)
  • Plastic box of 50 vials of lyophilisate (1 dose)
  • Plastic box of 100 vials of lyophilisate (1 dose)
  • Plastic box of 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of solvent (1 ml)
  • Plastic box of 100 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
  • Plastic box of 100 vials of lyophilisate (1 dose) and 100 vials of solvent (1 ml)
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V499164
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0306/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 21/05/2024
French (PDF)
Published on: 21/05/2024

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 21/05/2024
French (PDF)
Published on: 21/05/2024
German (PDF)
Published on: 21/05/2024

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 21/05/2024
French (PDF)
Published on: 21/05/2024
German (PDF)
Published on: 21/05/2024

eu-puar-frv0306001-mr-rpe792-en.pdf

English (PDF)
Published on: 7/01/2026
Download